From lysosomal storage diseases to NKT cell activation and back

International Journal of Molecular Sciences

Volumn 18, Issue 3, 2017, Pages

  Pereira, Cátia S ^a,b   Ribeiro, Helena ^a,b,c   Macedo, M Fatima ^a,b,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

Author keywords

CD1d; Lipids; Lysosomal storage diseases; Lysosome; NKT cells

Indexed keywords

LIPID TRANSFER PROTEIN; LYSOPHOSPHATIDYLCHOLINE; T LYMPHOCYTE RECEPTOR; CD1D ANTIGEN; CD1D PROTEIN, HUMAN;

AUTOIMMUNITY; AUTOPHAGY; CELL DIFFERENTIATION; CELL MIGRATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; LYSOSOME STORAGE DISEASE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PROTEIN EXPRESSION; REVIEW; ANIMAL; ENZYME REPLACEMENT; IMMUNOLOGY; LIPID METABOLISM; LYMPHOCYTE ACTIVATION; LYSOSOMAL STORAGE DISEASES; LYSOSOME; METABOLISM; PHENOTYPE; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, CD1D; ENZYME REPLACEMENT THERAPY; HUMANS; LIPID METABOLISM; LYMPHOCYTE ACTIVATION; LYSOSOMAL STORAGE DISEASES; LYSOSOMES; NATURAL KILLER T-CELLS; PHENOTYPE; T-LYMPHOCYTE SUBSETS;

EID: 85014064972     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18030502     Document Type: Review

References (84)

1. De Duve, C.; Pressman, B.C.; Gianetto, R.; Wattiaux, R.; Appelmans, F. Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochem. J. 1955, 60, 604–617. [CrossRef] [PubMed]
2. Segatori, L. Impairment of homeostasis in lysosomal storage disorders. IUBMB Life 2014, 66, 472–477. [CrossRef] [PubMed]
3. Parenti, G.; Andria, G.; Ballabio, A. Lysosomal storage diseases: From pathophysiology to therapy. Ann. Rev. Med. 2015, 66, 471–486. [CrossRef] [PubMed]
4. Alroy, J.; Garganta, C.; Wiederschain, G. Secondary biochemical and morphological consequences in lysosomal storage diseases. Biochem. Moscow 2014, 79, 619–636. [CrossRef] [PubMed]
5. Mori, L.; Lepore, M.; de Libero, G. The immunology of CD1- and MR1-restricted T cells. Ann. Rev. Immunol. 2016, 34, 479–510. [CrossRef] [PubMed]
6. Godfrey, D.I.; MacDonald, H.R.; Kronenberg, M.; Smyth, M.J.; van Kaer, L. NKT cells: What’s in a name? Nat. Rev. Immunol. 2004, 4, 231–237. [CrossRef] [PubMed]
7. Kumar, V.; Delovitch, T.L. Different subsets of natural killer T cells may vary in their roles in health and disease. Immunology 2014, 142, 321–336. [CrossRef] [PubMed]
8. Kohlgruber, A.C.; Donado, C.A.; LaMarche, N.M.; Brenner, M.B.; Brennan, P.J. Activation strategies for invariant natural killer T cells. Immunogenetics 2016, 68, 649–663. [CrossRef] [PubMed]
9. Rhost, S.; Sedimbi, S.; Kadri, N.; Cardell, S.L. Immunomodulatory type II natural killer T lymphocytes in health and disease. Scand. J. Immunol. 2012, 76, 246–255. [CrossRef] [PubMed]
10. Marrero, I.; Ware, R.; Kumar, V. Type II NKT cells in inflammation, autoimmunity, microbial immunity, and cancer. Front. Immunol. 2015, 6, 316. [CrossRef] [PubMed]
11. Rhost, S.; Lofbom, L.; Rynmark, B.-M.; Pei, B.; Mansson, J.-E.; Teneberg, S.; Blomqvist, M.; Cardell, S.L. Identification of novel glycolipid ligands activating a sulfatide-reactive, CD1d-restricted, type II natural killer T lymphocyte. Eur. J. Immunol. 2012, 42, 2851–2860. [CrossRef] [PubMed]
12. Maricic, I.; Girardi, E.; Zajonc, D.M.; Kumar, V. Recognition of lysophosphatidylcholine by type II NKT cells and protection from an inflammatory liver disease. J. Immunol. 2014, 193, 4580–4589. [CrossRef] [PubMed]
13. Nair, S.; Boddupalli, C.S.; Verma, R.; Liu, J.; Ruhua, Y.; Pastores, G.M.; Mistry, P.; Dhodapkar, M.V. Type II NKT-TFH cells against gaucher lipids regulate B cell immunity and inflammation. Blood 2014, 125, 1256–1271. [CrossRef] [PubMed]
14. Pereira, C.S.; Macedo, M.F. CD1-restricted T cells at the crossroad of innate and adaptive immunity. J. Immunol. Res. 2016, 2016, 2876275. [CrossRef] [PubMed]
15. Jahng, A.; Maricic, I.; Aguilera, C.; Cardell, S.; Halder, R.C.; Kumar, V. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J. Exp. Med. 2004, 199, 947–957. [CrossRef] [PubMed]
16. Arrenberg, P.; Halder, R.; Dai, Y.; Maricic, I.; Kumar, V. Oligoclonality and innate-like features in the TCR repertoire of type II NKT cells reactive to a β-linked self-glycolipid. Proc. Natl. Acad. Sci. USA 2010, 107, 10984–10989. [CrossRef] [PubMed]
17. Montoya, C.J.; Pollard, D.; Martinson, J.; Kumari, K.; Wasserfall, C.; Mulder, C.B.; Rugeles, M.T.; Atkinson, M.A.; Landay, A.L.; Wilson, S.B. Characterization of human invariant natural killer t subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6b11. Immunology 2007, 122, 1–14. [CrossRef] [PubMed]
18. Gumperz, J.E.; Miyake, S.; Yamamura, T.; Brenner, M.B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 2002, 195, 625–636. [CrossRef] [PubMed]
19. Berzins, S.P.; Smyth, M.J.; Baxter, A.G. Presumed guilty: Natural killer T cell defects and human disease. Nat. Rev. Immunol. 2011, 11, 131–142. [CrossRef] [PubMed]
20. Lynch, L.; O’Shea, D.; Winter, D.C.; Geoghegan, J.; Doherty, D.G.; O’Farrelly, C. Invariant NKT cells and CD1d+ cells amass in human omentum and are depleted in patients with cancer and obesity. Eur. J. Immunol. 2009, 39, 1893–1901. [CrossRef] [PubMed]
21. Lynch, L.; Nowak, M.; Varghese, B.; Clark, J.; Hogan, A.E.; Toxavidis, V.; Balk, S.P.; O’Shea, D.; O’Farrelly, C.; Exley, M.A. Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity 2012, 37, 574–587. [CrossRef] [PubMed]
22. Schipper, H.S.; Rakhshandehroo, M.; van de Graaf, S.F.; Venken, K.; Koppen, A.; Stienstra, R.; Prop, S.; Meerding, J.; Hamers, N.; Besra, G.; et al. Natural killer T cells in adipose tissue prevent insulin resistance. J. Clin. Investig. 2012, 122, 3343–3354. [CrossRef] [PubMed]
23. Wu, L.; Parekh, V.V.; Gabriel, C.L.; Bracy, D.P.; Marks-Shulman, P.A.; Tamboli, R.A.; Kim, S.; Mendez-Fernandez, Y.V.; Besra, G.S.; Lomenick, J.P.; et al. Activation of invariant natural killer T cells by lipid excess promotes tissue inflammation, insulin resistance, and hepatic steatosis in obese mice. Proc. Natl. Acad. Sci. USA 2012, 109, E1143–E1152. [CrossRef] [PubMed]
24. reg cells and macrophages in adipose tissue. Nat. Immunol. 2015, 16, 85–95. [CrossRef] [PubMed]
25. Lynch, L.; Hogan, A.E.; Duquette, D.; Lester, C.; Banks, A.; LeClair, K.; Cohen, D.E.; Ghosh, A.; Lu, B.; Corrigan, M.; et al. iNKT cells induce FGF21 for thermogenesis and are required for maximal weight loss in GLP1 therapy. Cell Metab. 2016, 24, 510–519. [CrossRef] [PubMed]
26. Satoh, M.; Hoshino, M.; Fujita, K.; Iizuka, M.; Fujii, S.; Clingan, C.S.; van Kaer, L.; Iwabuchi, K. Adipocyte-specific CD1d-deficiency mitigates diet-induced obesity and insulin resistance in mice. Sci. Rep. 2016, 6, 28473. [CrossRef] [PubMed]
27. Salio, M.; Silk, J.D.; Jones, E.Y.; Cerundolo, V. Biology of CD1- and MR1-restricted T cells. Ann. Rev. Immunol. 2014, 32, 323–366. [CrossRef] [PubMed]
28. Godfrey, D.I.; Stankovic, S.; Baxter, A.G. Raising the NKT cell family. Nat. Immunol. 2010, 11, 197–206. [CrossRef] [PubMed]
29. Lee, P.T.; Benlagha, K.; Teyton, L.; Bendelac, A. Distinct functional lineages of human Vα24 natural killer T cells. J. Exp. Med. 2002, 195, 637–641. [CrossRef] [PubMed]
30. Takahashi, T.; Chiba, S.; Nieda, M.; Azuma, T.; Ishihara, S.; Shibata, Y.; Juji, T.; Hirai, H. Cutting edge: Analysis of human Vα24+CD8+ NK T cells activated by α-galactosylceramide-pulsed monocyte-derived dendritic cells. J. Immunol. 2002, 168, 3140–3144. [CrossRef] [PubMed]
31. − invariant natural killer T cells. PLoS ONE 2011, 6, e28648.
32. Moreira-Teixeira, L.; Resende, M.; Coffre, M.; Devergne, O.; Herbeuval, J.P.; Hermine, O.; Schneider, E.; Rogge, L.; Ruemmele, F.M.; Dy, M.; et al. Proinflammatory environment dictates the IL-17-producing capacity of human invariant NKT cells. J. Immunol. 2011, 186, 5758–5765. [CrossRef] [PubMed]
33. Monteiro, M.; Almeida, C.F.; Agua-Doce, A.; Graca, L. Induced IL-17-producing invariant NKT cells require activation in presence of TGF-β and IL-1β. J. Immunol. 2013, 190, 805–811. [CrossRef] [PubMed]
34. Monteiro, M.; Agua-Doce, A.; Almeida, C.F.; Fonseca-Pereira, D.; Veiga-Fernandes, H.; Graca, L. IL-9 expression by invariant NKT cells is not imprinted during thymic development. J. Immunol. 2015, 195, 3463–3471. [CrossRef] [PubMed]
35. Cardell, S.; Tangri, S.; Chan, S.; Kronenberg, M.; Benoist, C.; Mathis, D. CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice. J. Exp. Med. 1995, 182, 993–1004. [CrossRef] [PubMed]
36. Park, S.H.; Weiss, A.; Benlagha, K.; Kyin, T.; Teyton, L.; Bendelac, A. The mouse cd1d-restricted repertoire is dominated by a few autoreactive T cell receptor families. J. Exp. Med. 2001, 193, 893–904. [CrossRef] [PubMed]
37. Exley, M.A.; Tahir, S.M.; Cheng, O.; Shaulov, A.; Joyce, R.; Avigan, D.; Sackstein, R.; Balk, S.P. A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses. J. Immunol. 2001, 167, 5531–5534. [CrossRef] [PubMed]
38. Exley, M.A.; He, Q.; Cheng, O.; Wang, R.J.; Cheney, C.P.; Balk, S.P.; Koziel, M.J. Cutting edge: Compartmentalization of Th1-like noninvariant CD1d-reactive T cells in hepatitis c virus-infected liver. J. Immunol. 2002, 168, 1519–1523. [CrossRef] [PubMed]
39. Chang, D.H.; Deng, H.; Matthews, P.; Krasovsky, J.; Ragupathi, G.; Spisek, R.; Mazumder, A.; Vesole, D.H.; Jagannath, S.; Dhodapkar, M.V. Inflammation-associated lysophospholipids as ligands for CD1D-restricted T cells in human cancer. Blood 2008, 112, 1308–1316. [CrossRef] [PubMed]
40. Bai, L.; Picard, D.; Anderson, B.; Chaudhary, V.; Luoma, A.; Jabri, B.; Adams, E.J.; Savage, P.B.; Bendelac, A. The majority of CD1D-sulfatide-specific T cells in human blood use a semiinvariant V∆1 TCR. Eur. J. Immunol. 2012, 42, 2505–2510. [CrossRef] [PubMed]
41. Prigozy, T.I.; Naidenko, O.; Qasba, P.; Elewaut, D.; Brossay, L.; Khurana, A.; Natori, T.; Koezuka, Y.; Kulkarni, A.; Kronenberg, M. Glycolipid antigen processing for presentation by CD1d molecules. Science 2001, 291, 664–667. [CrossRef] [PubMed]
42. Kinjo, Y.; Illarionov, P.; Vela, J.L.; Pei, B.; Girardi, E.; Li, X.; Li, Y.; Imamura, M.; Kaneko, Y.; Okawara, A.; et al. Invariant natural killer T cells recognize glycolipids from pathogenic gram-positive bacteria. Nat. Immunol. 2011, 12, 966–974. [CrossRef] [PubMed]
43. Zhou, D.; Mattner, J.; Cantu, C., 3rd; Schrantz, N.; Yin, N.; Gao, Y.; Sagiv, Y.; Hudspeth, K.; Wu, Y.P.; Yamashita, T.; et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004, 306, 1786–1789. [CrossRef] [PubMed]
44. Fox, L.M.; Cox, D.G.; Lockridge, J.L.; Wang, X.; Chen, X.; Scharf, L.; Trott, D.L.; Ndonye, R.M.; Veerapen, N.; Besra, G.S.; et al. Recognition of lyso-phospholipids by human natural killer T lymphocytes. PLoS Biol. 2009, 7, e1000228. [CrossRef] [PubMed]
45. Paduraru, C.; Bezbradica, J.S.; Kunte, A.; Kelly, R.; Shayman, J.A.; Veerapen, N.; Cox, L.R.; Besra, G.S.; Cresswell, P. Role for lysosomal phospholipase A2 in iNKT cell-mediated CD1d recognition. Proc. Natl. Acad. Sci. USA 2013, 110, 5097–5102. [CrossRef] [PubMed]
46. Kain, L.; Webb, B.; Anderson, B.L.; Deng, S.; Holt, M.; Costanzo, A.; Zhao, M.; Self, K.; Teyton, A.; Everett, C.; et al. The identification of the endogenous ligands of natural killer T cells reveals the presence of mammalian α-linked glycosylceramides. Immunity 2014, 41, 543–554. [CrossRef] [PubMed]
47. Kang, S.J.; Cresswell, P. Saposins facilitate CD1D-restricted presentation of an exogenous lipid antigen to T cells. Nat. Immunol. 2004, 5, 175–181. [CrossRef] [PubMed]
48. Zhou, D.; Cantu, C., III; Sagiv, Y.; Schrantz, N.; Kulkarni, A.B.; Qi, X.; Mahuran, D.J.; Morales, C.R.; Grabowski, G.A.; Benlagha, K.; et al. Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins. Science 2004, 303, 523–527. [CrossRef] [PubMed]
49. Yuan, W.; Qi, X.; Tsang, P.; Kang, S.J.; Illarionov, P.A.; Besra, G.S.; Gumperz, J.; Cresswell, P. Saposin b is the dominant saposin that facilitates lipid binding to human CD1d molecules. Proc. Natl. Acad. Sci. USA 2007, 104, 5551–5556. [CrossRef] [PubMed]
50. Salio, M.; Ghadbane, H.; Dushek, O.; Shepherd, D.; Cypen, J.; Gileadi, U.; Aichinger, M.C.; Napolitani, G.; Qi, X.; van der Merwe, P.A.; et al. Saposins modulate human invariant natural killer T cells self-reactivity and facilitate lipid exchange with CD1d molecules during antigen presentation. Proc. Natl. Acad. Sci. USA 2013, 110, E4753–E4761. [CrossRef] [PubMed]
51. Schrantz, N.; Sagiv, Y.; Liu, Y.; Savage, P.B.; Bendelac, A.; Teyton, L. The niemann-pick type C2 protein loads isoglobotrihexosylceramide onto CD1d molecules and contributes to the thymic selection of NKT cells. J. Exp. Med. 2007, 204, 841–852. [CrossRef] [PubMed]
52. de la Salle, H.; Mariotti, S.; Angenieux, C.; Gilleron, M.; Garcia-Alles, L.F.; Malm, D.; Berg, T.; Paoletti, S.; Maitre, B.; Mourey, L.; et al. Assistance of microbial glycolipid antigen processing by CD1e. Science 2005, 310, 1321–1324. [CrossRef] [PubMed]
53. Facciotti, F.; Cavallari, M.; Angenieux, C.; Garcia-Alles, L.F.; Signorino-Gelo, F.; Angman, L.; Gilleron, M.; Prandi, J.; Puzo, G.; Panza, L.; et al. Fine tuning by human CD1e of lipid-specific immune responses. Proc. Natl. Acad. Sci. USA 2011, 108, 14228–14233. [CrossRef] [PubMed]
54. De Libero, G.; Mori, L. Novel insights into lipid antigen presentation. Trends Immunol. 2012, 33, 103–111. [CrossRef] [PubMed]
55. Chiu, Y.H.; Jayawardena, J.; Weiss, A.; Lee, D.; Park, S.H.; Dautry-Varsat, A.; Bendelac, A. Distinct subsets of cd1d-restricted T cells recognize self-antigens loaded in different cellular compartments. J. Exp. Med. 1999, 189, 103–110. [CrossRef] [PubMed]
56. Chiu, Y.H.; Park, S.H.; Benlagha, K.; Forestier, C.; Jayawardena-Wolf, J.; Savage, P.B.; Teyton, L.; Bendelac, A. Multiple defects in antigen presentation and T cell development by mice expressing cytoplasmic tail-truncated CD1d. Nat. Immunol. 2002, 3, 55–60. [CrossRef] [PubMed]
57. Chen, X.; Wang, X.; Keaton, J.M.; Reddington, F.; Illarionov, P.A.; Besra, G.S.; Gumperz, J.E. Distinct endosomal trafficking requirements for presentation of autoantigens and exogenous lipids by human CD1d molecules. J. Immunol. 2007, 178, 6181–6190. [CrossRef] [PubMed]
58. Salio, M.; Puleston, D.J.; Mathan, T.S.; Shepherd, D.; Stranks, A.J.; Adamopoulou, E.; Veerapen, N.; Besra, G.S.; Hollander, G.A.; Simon, A.K.; et al. Essential role for autophagy during invariant NKT cell development. Proc. Natl. Acad. Sci. USA 2014, 111, E5678–E5687. [CrossRef] [PubMed]
59. Pei, B.; Zhao, M.; Miller, B.C.; Vela, J.L.; Bruinsma, M.W.; Virgin, H.W.; Kronenberg, M. Invariant nkt cells require autophagy to coordinate proliferation and survival signals during differentiation. J. Immunol. 2015, 194, 5872–5884. [CrossRef] [PubMed]
60. Schumann, J.; Facciotti, F.; Panza, L.; Michieletti, M.; Compostella, F.; Collmann, A.; Mori, L.; de Libero, G. Differential alteration of lipid antigen presentation to NKT cells due to imbalances in lipid metabolism. Eur. J. Immunol. 2007, 37, 1431–1441. [CrossRef] [PubMed]
61. Gadola, S.D.; Silk, J.D.; Jeans, A.; Illarionov, P.A.; Salio, M.; Besra, G.S.; Dwek, R.; Butters, T.D.; Platt, F.M.; Cerundolo, V. Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases. J. Exp. Med. 2006, 203, 2293–2303. [CrossRef] [PubMed]
62. Sagiv, Y.; Hudspeth, K.; Mattner, J.; Schrantz, N.; Stern, R.K.; Zhou, D.; Savage, P.B.; Teyton, L.; Bendelac, A. Cutting edge: Impaired glycosphingolipid trafficking and NKT cell development in mice lacking niemann-pick type c1 protein. J. Immunol. 2006, 177, 26–30. [CrossRef] [PubMed]
63. Darmoise, A.; Teneberg, S.; Bouzonville, L.; Brady, R.O.; Beck, M.; Kaufmann, S.H.; Winau, F. Lysosomal α-galactosidase controls the generation of self lipid antigens for natural killer T cells. Immunity 2010, 33, 216–228. [CrossRef] [PubMed]
64. Macedo, M.F.; Quinta, R.; Pereira, C.S.; Sa Miranda, M.C. Enzyme replacement therapy partially prevents invariant natural killer T cell deficiency in the fabry disease mouse model. Mol. Genet. Metab. 2012, 106, 83–91. [CrossRef] [PubMed]
65. Porubsky, S.; Speak, A.O.; Salio, M.; Jennemann, R.; Bonrouhi, M.; Zafarulla, R.; Singh, Y.; Dyson, J.; Luckow, B.; Lehuen, A.; et al. Globosides but not isoglobosides can impact the development of invariant NKT cells and their interaction with dendritic cells. J. Immunol. 2012, 189, 3007–3017. [CrossRef] [PubMed]
66. Plati, T.; Visigalli, I.; Capotondo, A.; Buono, M.; Naldini, L.; Cosma, M.P.; Biffi, A. Development and maturation of invariant NKT cells in the presence of lysosomal engulfment. Eur. J. Immunol. 2009, 39, 2748–2754. [CrossRef] [PubMed]
67. Balreira, A.; Lacerda, L.; Miranda, C.S.; Arosa, F.A. Evidence for a link between sphingolipid metabolism and expression of CD1d and MHC-class II: Monocytes from gaucher disease patients as a model. Br. J. Haematol. 2005, 129, 667–676. [CrossRef] [PubMed]
68. Balreira, A.; Macedo, M.F.; Girao, C.; Rodrigues, L.G.; Oliveira, J.P.; Sa Miranda, M.C.; Arosa, F.A. Anomalies in conventional T and invariant natural killer T-cell populations in fabry mice but not in fabry patients. Br. J. Haematol. 2008, 143, 601–604. [CrossRef] [PubMed]
69. Rozenfeld, P.; Agriello, E.; de Francesco, N.; Martinez, P.; Fossati, C. Leukocyte perturbation associated with fabry disease. J. Inherit. Metab. Dis. 2009, 32, S67–S77. [CrossRef] [PubMed]
70. Speak, A.O.; Platt, N.; Salio, M.; te Vruchte, D.; Smith, D.A.; Shepherd, D.; Veerapen, N.; Besra, G.S.; Yanjanin, N.M.; Simmons, L.; et al. Invariant natural killer T cells are not affected by lysosomal storage in patients with niemann-pick disease type c. Eur. J. Immunol. 2012, 42, 1886–1892. [CrossRef] [PubMed]
71. Pereira, C.S.; Azevedo, O.; Luz Maia, M.; Dias, A.F.; Sa-Miranda, C.; Fatima Macedo, M. Invariant natural killer T cells are phenotypically and functionally altered in fabry disease. Mol. Genet. Metab. 2013, 108, 241–248. [CrossRef] [PubMed]
72. Vartabedian, V.F.; Savage, P.B.; Teyton, L. The processing and presentation of lipids and glycolipids to the immune system. Immunol. Rev. 2016, 272, 109–119. [CrossRef] [PubMed]
73. Berzins, S.P.; Cochrane, A.D.; Pellicci, D.G.; Smyth, M.J.; Godfrey, D.I. Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples. Eur. J. Immunol. 2005, 35, 1399–1407. [CrossRef] [PubMed]
74. Biancini, G.B.; Vanzin, C.S.; Rodrigues, D.B.; Deon, M.; Ribas, G.S.; Barschak, A.G.; Manfredini, V.; Netto, C.B.; Jardim, L.B.; Giugliani, R.; et al. Globotriaosylceramide is correlated with oxidative stress and inflammation in fabry patients treated with enzyme replacement therapy. Biochim. Biophys. Acta 2012, 1822, 226–232. [CrossRef] [PubMed]
75. Hollak, C.E.; van Weely, S.; van Oers, M.H.; Aerts, J.M. Marked elevation of plasma chitotriosidase activity. A novel hallmark of gaucher disease. J. Clin.Investig. 1994, 93, 1288–1292. [CrossRef] [PubMed]
76. Facciotti, F.; Ramanjaneyulu, G.S.; Lepore, M.; Sansano, S.; Cavallari, M.; Kistowska, M.; Forss-Petter, S.; Ni, G.; Colone, A.; Singhal, A.; et al. Peroxisome-derived lipids are self antigens that stimulate invariant natural killer T cells in the thymus. Nat. Immunol. 2012, 13, 474–480. [CrossRef] [PubMed]
77. Pereira, C.S.; Sa-Miranda, C.; De Libero, G.; Mori, L.; Macedo, M.F. Globotriaosylceramide inhibits iNKT-cell activation in a CD1d-dependent manner. Eur. J. Immunol. 2016, 46, 147–153. [CrossRef] [PubMed]
78. Pastores, G.M.; Hughes, D.A. Non-neuronopathic lysosomal storage disorders: Disease spectrum and treatments. Best Pract. Res. Clin. Endocrinol. Metab. 2015, 29, 173–182. [CrossRef] [PubMed]
79. Bennett, L.L.; Mohan, D. Gaucher disease and its treatment options. Ann. Pharmacother. 2013, 47, 1182–1193. [CrossRef] [PubMed]
80. Grabowski, G.A.P.; Edwin, H. Kolodny Gaucher Disease. In The Online Metabolic and Molecular Bases of Inherited Disease; Valle, D., Beaudet, A.L., Vogelstein, B., Kinzler, K.W., Antonarakis, S.E., Ballabio, A., Gibson, K.M., Mitchell, G., Eds.; McGraw-Hill Medical: New York, NY, USA, 2013.
81. Hollak, C.E.; Weinreb, N.J. The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in gaucher and fabry disease. Best Pract. Res. Clin. Endocrinol. Metab. 2015, 29, 205–218. [CrossRef] [PubMed]
82. Choy, F.Y.; Campbell, T.N. Gaucher disease and cancer: Concept and controversy. Int. J. Cell Biol. 2011, 2011, 150450. [CrossRef] [PubMed]
83. Vitner, E.B.; Platt, F.M.; Futerman, A.H. Common and uncommon pathogenic cascades in lysosomal storage diseases. J. Biol. Chem. 2010, 285, 20423–20427. [CrossRef] [PubMed]
84. Killedar, S.; Dirosario, J.; Divers, E.; Popovich, P.G.; McCarty, D.M.; Fu, H. Mucopolysaccharidosis IIIb, a lysosomal storage disease, triggers a pathogenic CNS autoimmune response. J. Neuroinflamm. 2010, 7, 39. [CrossRef] [PubMed]